
NeurologyLive® Friday 5 — October 23, 2026
Key Takeaways
- Clinical awareness of social determinants and broader telehealth adoption are positioned as actionable levers to reduce stroke recurrence, particularly for patients facing barriers to longitudinal cerebrovascular care.
- Neuropsychology-informed approaches can improve detection, characterization, and treatment planning for cognitive dysfunction in multiple sclerosis, reframing assessment beyond routine bedside screening.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Don’t have time to read or watch a full video interview?
Click the read more or watch now buttons for more details and information about each highlight.
1: Differentiating FcRn-Targeted Therapies in MG Clinical Practice
In the latest episode of a Peer Exchange video series, titled “Differentiating FcRn-Targeted Therapies in MG Clinical Practice,” panelists Suraj Muley, MD, FAAN, FACP, Karissa Gable, MD, Beth Stein, MD, and Joshua Alpers, MD, examining clinically relevant differences among available FcRn-targeted therapies in myasthenia gravis.
2: Diagnosing TK2D: Clinical Red Flags and Genetic Testing First
In the latest episode of a Peers & Perspectives video series, titled "Diagnosing TK2D: Clinical Red Flags and Genetic Testing First," Michio Hirano, MD, and Zarazuela Zolkipli-Cunningham, MBChB, MRCP, discuss the human cost of diagnostic delay and moves to practical testing decisions in TK2D.
3: Assessing the Quality-of-Life Burden of MG
In the latest episode of a Peer Exchange video series, titled “Assessing the Quality-of-Life Burden of MG," panelists James F. Howard Jr., MD, Tuan Vu, MD, Ali Habib, MD, and Pushpa Narayanaswami, MD, explore the clinical and functional factors that influence how quickly treatment should be initiated and how intensive that treatment should be for MG.
4: NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS
In a recent Q&A interview, Bruce Bebo, PhD, chief research and medical affairs officer at the National MS Society, discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.
5: Follow-Up Care and the Caregiver's Role in Managing Agitation
In the latest episode of a Peer Exchange video series, titled "Follow-Up Care and the Caregiver's Role in Managing Agitation," panelists Marwan Sabbagh, MD, Amita Patel, MD, CMD, MHA, CPE, Erin Crown, MHS, PA-C, Psych-CAQ, David Liporace, DO, and Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC, close the series with a look at follow-up ownership and the caregiver's central role in managing agitation.
Which conversation stood out most to you in this week’s NeurologyLive Friday Five?
Related to this article







